science
plus
.abes.fr
|
explorer
À propos de :
Advances in targeted therapies II
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
bibo:Issue
, within Data Space :
scienceplus.abes.fr
associated with source
document(s)
Type:
work
Issue
New Facet based on Instances of this Class
Attributs
Valeurs
type
work
Issue
Is Part Of
http://hub.abes.fr/bmj/periodical/ard/2000/volume_59
Title
Advances in targeted therapies II
has manifestation of work
http://hub.abes.fr/bmj/periodical/ard/2000/volume_59/issue_suppl1/m/web
http://hub.abes.fr/bmj/periodical/ard/2000/volume_59/issue_suppl1/m/print
Date Copyrighted
2000
Rights
Annals of the Rheumatic Diseases
issue
suppl 1
is
Is Part Of
of
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
Clinical outcome measures in rheumatoid arthritis
Etanercept (Enbrel): update on therapeutic use
Biological role of interleukin 1 receptor antagonist isoforms
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α
Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-κB
Efficacy and toxicity of old and new disease modifying antirheumatic drugs
Arguments for interleukin 1 as a target in chronic arthritis
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFκB in tumour necrosis factor production
The final pathogenetic steps in focal bone erosions in rheumatoid arthritis
Activation of cytokines as a mechanism of disease progression in heart failure
Which post-marketing database and studies does EMEA require
The role of angiogenesis in rheumatoid arthritis: recent developments
The role of national agencies in the managed introduction of new drugs for arthritis
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences
Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system
Jaks and Stats as therapeutic targets
Advances in interleukin 2 receptor targeted treatment
Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update
Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis
Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody
Advances in targeted therapies II
Targeting interleukin 18 with interleukin 18 binding protein
Post-transcriptional regulation of tumour necrosis factor α production
Future prospects for anti-cytokine treatment
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Alternative Linked Data Documents:
ODE
Content Formats:
RDF
ODATA
Microdata
